Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)
Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%
Immunocore price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Immunocore's price to sales ratio was 3.8× on Nov 11, 2026, against 5.3× a year earlier. Over the last 5 years it ranged from 0.2× to 72.3×, with a median of 4.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.8× | −0.8 |
| 2025 | Dec 31, 2025 | 4.6× | −0.4 |
| 2024 | Dec 31, 2024 | 5.0× | −13.9 |
| 2023 | Dec 29, 2023 | 18.8× | +18.5 |
| 2022 | Dec 30, 2022 | 0.3× | – |
See a number that looks wrong?